Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

sandoz do brasil indÚstria farmacÊutica ltda - antimicotico

Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

isofarma industrial farmacÊutica ltda - antimicotico

Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

sandoz do brasil indÚstria farmacÊutica ltda - antimicoticos sistemicos

Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

cristÁlia produtos quÍmicos farmacÊuticos ltda. - fluconazol - anti-fungicos

Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

diffucap - chemobrÁs quÍmica e farmacÊutica ltda - fluconazol - antimicoticos sistemicos

Brasilia - portugali - CPVS (Compêndio de Produtos Veterinários)

zoetis indÚstria de produtos veterinÁrios ltda - Óleo mineral; - outros

Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

1farma industria farmaceutica ltda - fluconazol - antimicotico

Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

ativus farmacÊutica ltda - antimicotico

Euroopan unioni - portugali - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant pode ser usado como monoterapia ou em combinação com metotrexato. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Euroopan unioni - portugali - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrite, reumatóide - imunossupressores - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.